Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.605
-0.055 (-1.50%)
At close: Aug 26, 2026, 4:00 PM EDT
3.495
-0.110 (-3.05%)
Pre-market: Aug 27, 2026, 4:00 AM EDT
Anixa Biosciences Employees
Anixa Biosciences had 4 employees as of October 31, 2025. The number of employees decreased by 1 or -20.00% compared to the previous year.
Employees
4
Change (1Y)
-1
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$2,508,500
Market Cap
122.65M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 4 | -1 | -20.00% | 4 | 0 |
| Oct 31, 2024 | 5 | 0 | - | 5 | 0 |
| Oct 31, 2023 | 5 | 0 | - | 4 | 1 |
| Oct 31, 2022 | 5 | 0 | - | 4 | 1 |
| Oct 31, 2021 | 5 | 1 | 25.00% | 4 | 1 |
| Oct 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Oct 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cibus | 118 |
| Inovio Pharmaceuticals | 112 |
| Fractyl Health | 100 |
| enGene Therapeutics | 82 |
| Rani Therapeutics Holdings | 71 |
| Vivani Medical | 42 |
| Biomea Fusion | 37 |
| Genelux | 26 |
ANIX News
- 2 days ago - Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy - PRNewsWire
- 8 days ago - Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire
- 6 weeks ago - Anixa Biosciences granted Australian patent for breast cancer vaccine - TheFly
- 6 weeks ago - Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology - PRNewsWire
- 7 weeks ago - Anixa Biosciences, Moffitt Cancer advance ovarian cancer CAR-T trial - TheFly
- 7 weeks ago - Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date - PRNewsWire
- 2 months ago - Anixa Biosciences assumed with a Buy at D. Boral Capital - TheFly
- 2 months ago - Anixa Biosciences granted first Korean patent for breast cancer vaccine - TheFly